- 80 experts object to a proposal to slap a 95% tax on drugs that do not submit to price controls.
- China has matched the United States in output in seven high-tech sectors, including pharmaceuticals and medical products.
- If worry about climate change is a mental health issue, why is the W.H.O. contributing to the problem?
- The good news on immigration.
Category: Policy & Legislation
The FTC wants to Know if Middlemen Increase Drug Prices
The Federal Trade Commission (FTC) is opening an investigation into the business practices of pharmacy benefit managers (PBMs). PBMs have been in the hotseat for quite some time. Executives from the largest PBMs were recently called to testify before Congress to explain whether their business practices lead to higher drug prices. In the latest inquiry, the FTC announced it will require the six largest PBMs to provide a range of information and business records on operations.
Who Does the AARP Represent?
The AARP, the legendary advocacy for seniors aged 50 and above, has come under increased scrutiny in recent years for its marketing partnerships. Much of AARP’s revenue comes from licensing its name and logo to sell a wide range of goods and services targeted to seniors. The AARP is undoubtedly a senior advocacy, but it is also a marketing juggernaut that sells insurance.